Study of CXA-10 in Healthy Volunteers

NCT02127190 | Completed Phase 1

• 1 other identifier: CXA-10-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety and tolerability of the rate of the emulsion vehicle infusion in healthy volunteers. In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.

Conditions

Acute Kidney Injury (Nontraumatic)

Keywords

nitro-fatty acids; anti-inflammatory; Nrf2 activation; contrast induced AKI

Outcome Measures

Primary Outcomes (1)

• Number of subjects with Serious and Non-Serious Adverse Events

  First day of dosing through 30 days after the last dose

Study Arms (2)

CXA-10 placebo emulsion

PLACEBO COMPARATOR

single intravenous dose of CXA 10 placebo emulsion

Drug: Placebo

CXA-10 Emulsion

EXPERIMENTAL

single ascending intravenous doses of CXA-10 emulsion

Drug: CXA-10 emulsion

Interventions

CXA-10 emulsion DRUG

CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.

CXA-10 Emulsion

Placebo DRUG

CXA-10 placebo emulsion

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male subjects and female subjects of non-child bearing potential between the ages of 18 and 50 years (inclusive)
• Females must not be of child bearing potential (defined as bilateral oophorectomy, hysterectomy, or post-menopausal \[amenorrhea for minimum of 1 year and post-menopausal status confirmed by follicle stimulating hormone (FSH) testing\]). Female subjects unable to bear children (e.g. tubal ligation, hysterectomy, or post-menopausal) must have this documented in the case report form (CRF).
• Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and a weight between 60 kg and 100 kg (inclusive)-Part A and B only
• BMI between 30 and 50 kg/m2 for subjects in Part C only
• In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis. Subjects in Part C only may be allowed to have blood pressure readings up to160/100.
• Subjects must have resting heart rates (HR) ≥50 beats per minute at baseline
• QTcF interval (Fredericia's correction factor) of the baseline ECG must be ≤430 msec for males and ≤450 msec for females at screening and predose. Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study. Subjects with a history of congenital long QT syndrome in the subject or in the subject's family will be excluded from the study (see Section 6.4.3.
• Adequate bilateral venous access to allow for repeated dose infusions and blood sampling
• Ability to comprehend and comply with procedures
• Agree to commit to participate in the current protocol
• Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)

You may not qualify if:

• Female subjects who are pregnant or lactating or who are trying to conceive
• Female subjects with a positive urine β-human chorionic gonadotropin (β-hCG) test at screening and Day -1 for any dosing day
• Any clinically relevant abnormality identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
• Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations, personal or family history of congenital prolonged QT syndromes
• History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
• Past history of pancreatitis
• History of documented hypersensitivity reaction to eggs or egg products (as vehicle contains egg phospholipids)
• History of documented hypersensitivity reaction to soy or soy products (as vehicle contains soy bean oil)
• History of regular alcohol consumption exceeding 14 units/week for women or 21 units/week for men (one unit = 125 mL of wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of screening
• History of smoking or use of nicotine-containing products within the past 6 months
• Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements) within seven days or five half-lives, whichever is longer, prior to dosing and until collection of the final PK sample. Use of any drug including aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior to the first dose and during this study as it will interfere with the pharmacology of CXA-10. Use of high energy supplements or drinks (especially, those containing caffeine, protein supplements, and weight loss drugs) and smoking cessation products (gum, inhalers, patches) will be prohibited.
• Only acetaminophen will be permitted at doses of -2 grams/day
• Sitting blood pressure \>140 mmHg systolic and/or \>90 mmHg diastolic after 5 minutes rest (feet on floor, arm held at level of heart) at the screening visit for subjects who participate in Parts A and B. Subjects in Part C only may be allowed to have blood pressure readings up to 160 mmHg systolic and up to 100 mmHg diastolic
• Resting heart rate ≥100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit
• Any abnormalities on 12-lead ECG at screening including, but not limited to any of the following

Sponsors & Collaborators

• Complexa, Inc.: lead

Study Sites (1)

Jasper Clinical Research & Development, Inc.

Kalamazoo, Michigan, 49007, United States

Location

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• James VanderLugt, MD

  Jasper Clinic, Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 24, 2014
• First Posted: April 30, 2014
• Study Start: April 1, 2014
• Primary Completion: September 1, 2014
• Study Completion: December 1, 2014
• Last Updated: February 1, 2018

Record last verified: 2016-05

Locations

US (1)